This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/SCE865. CME/AAPA credit will be available until December 18, 2026.

First Move Matters: Playing to Win in EoE – From Emergency Department Recognition to Continued Care Strategies

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NAW865. CME/MOC/NCPD/AAPA/IPCE credit will be available until July 6, 2026.

Expanding the Bispecific Option Across Hematologic Cancers: Guidance for the Community on Collaborative Care and Accessing Innovative Immunotherapy for Myeloma and Lymphoma

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/JCA865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until May 26, 2026.

AD-SAFE: An Initiative to Build Understanding of ARIA and Skills Needed to Guide Treatment Decisions and Support Rapid Recognition and Response in Radiology

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RAX865. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 20, 2026.

Navigating Multifactorial Clinical Decisions in HR+ EBC and MBC: A Case-Based, Algorithmic Guide

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by educational grants from Genentech, a member of the Roche Group, Lilly, and Stemline Therapeutics, a Menarini Company Group.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE information, and to apply for credit, please visit us at PeerView.com/NDZ865. CME/MOC/NCPD/AAPA/ASWB-ACE/APA/IPCE credit will be available until June 18, 2026.

Remembering Brain Health: Reshaping Care Models to Achieve Meaningful Impact Across the Lifespan

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and BrightFocus Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/BRK865. CME/MOC/NCPD/AAPA credit will be available until April 29, 2026.

Exploring the Promise of Biomarkers and ATTs in Diagnosing and Treating Early Symptomatic Alzheimer’s Disease: Key Takeaways From AD/PD 2025 and AAN 2025

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Lilly.

Disclosure information is available at the beginning of the video presentation

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/UYH865. CME/MOC/NCPD/AAPA/IPCE credit will be available until April 14, 2026.

A New Era in Treating Advanced Ovarian Cancer: Practical Tips for Maximizing the Use of PARP Inhibitors, Immunotherapy, and ADCs

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Foundation for Women’s Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca, Merck & Co., Inc., Rahway, NJ, USA, and Sutro Biopharma, Inc.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/STT865. CME/MOC/AAPA/IPCE credit will be available until March 14, 2026.

Maximizing Therapeutic Innovations in Bladder Cancer: Expert Strategies for Comprehensive Care Across Disease Stages

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Bladder Cancer Advocacy Network. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CFZ865. CME/MOC/AAPA/IPCE credit will be available until February 23, 2026.

Strengthening the Immunotherapy Paradigm in Advanced SCAC: Established & Emerging Roles of Immune-Based Platforms Across Lines of Therapy

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and The Anal Cancer Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Incyte Corporation.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete NCPD/ILNA information, and to apply for credit, please visit us at PeerView.com/XRZ865. NCPD/ILNA credit will be available until December 30, 2025.

Personalized Care and Tailored Treatment Plans for Gynecologic Cancers: Practical Nurse Guidance on Utilizing Modern Therapeutic Approaches

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, Foundation for Women’s Cancer, and National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AbbVie, AstraZeneca, Daiichi Sankyo, and Pfizer Inc. and Genmab.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/CPE information, and to apply for credit, please visit us at PeerView.com/VPZ865. CME/CPE credit will be available until December 10, 2025.

Optimizing PARP Inhibitor Therapy in Veterans With Prostate Cancer: A Practical Guide for VA Pharmacists

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and ZERO Prostate Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by independent educational grants from AstraZeneca and Merck & Co., Inc., Rahway, NJ, USA.

Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.

For the full presentation, downloadable Practice Aids, slides, and complete CME/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/UHT865. CME/NCPD/AAPA credit will be available until October 31, 2025.

The New Normal: Digital Technologies for People Living With Insulin-Treated Type 2 Diabetes

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support
This activity is supported by an educational grant from Novo Nordisk Inc.

Disclosure information is available at the beginning of the video presentation.

Go online to PeerView.com/VWR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Due to the rarity of Rett syndrome and overlapping symptoms with other, more common neurodevelopmental disorders, diagnosis is challenging and often missed or delayed. With one Rett-targeted therapy recently approved and others in development, clinicians now have the opportunity to offer not merely symptom management but potential clinical improvement. This PeerView case-based activity is designed to improve your ability to recognize, diagnose, and treat patients with Rett syndrome. Each session features a realistic case discussion with expert faculty panelists sharing the evidence that supports clinical decisions for timely diagnosis and early initiation of multidisciplinary management and targeted therapy as appropriate. Upon completion of this activity, participants should be better able to: Apply diagnostic criteria to provide a timely diagnosis of Rett syndrome in patients demonstrating subtle signs and symptoms; Employ evidence-based, age-appropriate care for patients with Rett syndrome in alignment with consensus management guidelines; and Evaluate the evidence surrounding the safety, efficacy, and tolerability of new and emerging therapies for the treatment of Rett syndrome.

Go online to PeerView.com/CTH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Myelin oligodendrocyte glycoprotein antibody-associated disorder (MOGAD) was identified as a distinct demyelinating disease entity only recently. Prior to this characterization of MOGAD, many patients were considered to have a variant of MS, NMOSD, or other neurologic condition. Now an international panel of experts has proposed diagnostic criteria that, when validated, promise to improve MOGAD diagnostic accuracy and confidence. This is particularly important, given that several clinical trials are investigating potential treatments for MOGAD. This unique PeerView activity will use problem-based educational interventions to expose learners to the science and clinical experience behind accurate diagnosis and best practices in management of MOGAD. You will be able to employ optimal clinical decision-making for your patients with MOGAD that is based on the latest evidence, best practice recommendations, and effective interdisciplinary collaboration. Upon completion of this activity, participants should be better able to: Explain the diagnostic criteria for MOGAD as proposed by the International MOGAD Panel; Employ recommended diagnostic tools (eg, the MOG antibody test, relevant MRI findings) to identify MOGAD and distinguish it from other demyelinating diseases; and Implement therapeutic strategies to provide acute treatment and relapse prevention in patients with MOGAD.

Go online to PeerView.com/JDT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the factors that contribute to people living with HIV (PLWH) falling out of care, the barriers associated with different strategies for re-engaging PLWH, and individualized plans that can be used for re-engaging PLWH back into care. Upon completion of this activity, participants should be better able to: Identify individual and structural factors that contribute to PLWH falling out of care; Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care; and Employ individualized and comprehensive plans to successfully re-engage PLWH in care.

Go online to PeerView.com/BPX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. While homozygous familial hypercholesterolemia (HoFH) is associated with development of atherosclerotic cardiovascular disease in childhood, early recognition and treatment of this inherited disease can improve outcomes for patients. In this animated activity provided by PeerView in collaboration with the Family Heart Foundation, a cardiologist describes the impact of this rare disease on patients and their families, presents strategies for recognizing signs and symptoms of HoFH, and reviews guidelines for genetic screening and referral of patients and their families to appropriate experts and resources for support. Additionally, two patients share their experiences of living with HoFH. Upon completion of this activity, participants should be better able to: Describe the consequences of undiagnosed and untreated HoFH from the patient’s perspective; Distinguish hallmark signs, symptoms, and family history differentiating HoFH from other disorders; and Employ current guidelines and support resources to direct patients with suspected HoFH to appropriately qualified care providers.

Go online to PeerView.com/QYD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the choice of regimens for patients with hepatocellular carcinoma (HCC) continues to expand with new standard-of-care therapies for advanced disease, and emerging innovative locoregional and multimodal strategies for early- and intermediate-stage disease, clinicians who treat liver cancer have increased opportunities to collaborate with colleagues and improve patient outcomes. Designed to guide professionals into a new era of team-based personalized care, this Seminars & Tumor Board activity features a multidisciplinary panel of experts who will link current science and treatment recommendations to practical guidance on therapeutic decision-making. Using case-based discussion, the expert panel will address a variety of clinical issues such as treatment selection, sequencing, and the integration of systemic therapy with locoregional management. It takes a team to provide the best care for your patients—participate in this activity to hear the latest on using collaborative strategies to optimize outcomes in HCC. Upon completion of this activity, participants should be better able to: Evaluate the efficacy/safety profiles and clinical roles of novel and emerging systemic therapy approaches for patients with advanced/metastatic HCC; Review the latest evidence on innovative strategies, including novel locoregional modalities, combinations of locoregional and systemic therapies, and perioperative/conversion approaches, for patients with HCC across the disease continuum; Develop contemporary, personalized management plans for patients with HCC that consider the available clinical evidence, expert/guideline recommendations, clinical trial opportunities, and patient-, disease-, and treatment-specific factors; and Implement best practices for multidisciplinary collaboration and care coordination when managing patients with HCC, including team-based strategies to maximize treatment efficacy, safety, tolerability, and patient quality of life.

Go online to PeerView.com/PUE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Gene fusions and other key alterations (NTRK, RET, and others) represent actionable targets in a substantial proportion of patients with solid tumors. Appropriate biomarker testing is crucial to identify all alterations that are treatable with current or investigational targeted therapies. Multikinase tyrosine kinase inhibitors (TKIs) have been used to treat such alterations, but they have limited efficacy. Therefore, next-generation TKIs with greater selectivity have been developed and approved for tumor-agnostic indications (such as NTRK alterations) and for specific tumor types (such as RET alterations in lung and thyroid cancers). These newer therapies have demonstrated impressive efficacy with favorable safety profiles, and their use can significantly improve patient outcomes and quality of life. The tumor-agnostic indications are anticipated to expand further, and novel options are also emerging for patients who have developed resistance to standard RET- and TRK-targeted therapies. In this PeerView educational offering, experts on gene fusion-positive solid tumors provide a cutting-edge update on the role and relevance of gene fusions and other key alterations in solid tumors. These KOLs offer guidance on how to best identify patients with gene alterations and discuss accumulating clinical evidence for the best use of targeted therapies, while also providing practical guidance for optimizing multidisciplinary and interprofessional strategies for biomarker testing and use of targeted therapy across solid tumors harboring NTRK and RET fusions and other actionable alterations. Upon completion of this activity, participants should be better able to: Describe the role of NTRK, RET, ALK, and other key genomic alterations in the oncogenesis of solid tumors, the importance of appropriate biomarker testing to identify patients with these alterations, and clinical evidence supporting the use of matched targeted therapies to optimize patient outcomes; Collaborate with the broader cancer care team to identify patients for biomarker testing, select appropriate tests to capture all relevant genomic alterations, including gene fusions, and interpret testing results to guide treatment selection; Apply the latest evidence and guidelines to individualize targeted therapy for patients with cancers harboring NTRK, RET, ALK, and other targetable genomic alterations; and Educate patients about the role of biomarker testing, risks and benefits of targeted therapies, and importance of selecting optimal therapy based on biomarker testing results and patient needs, values, and preferences.

Go online to PeerView.com/FJH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated educational activity, an expert in chronic inflammatory demyelinating polyneuropathy (CIDP) discusses the diagnosis, assessment, treatment, and monitoring of the disease. A patient also shares her experiences living with and treating her CIDP. Upon completion of this activity, participants should be better able to: Apply guideline-directed criteria to diagnose chronic inflammatory demyelinating polyneuropathy (CIDP), including correct interpretation of electrodiagnostic findings; Incorporate evidence surrounding efficacy, safety, and tolerability of recommended pharmacotherapies (eg, corticosteroids, IVIg, SCIg, and plasma exchange) and shared decision-making into CIDP treatment planning; and Employ validated assessment tools to monitor treatment response and guide clinical decision-making.